Structural requirement of tunicamycin V for MraY inhibition.

Anti-Bacterial Agents / chemical synthesis Bacterial Proteins / antagonists & inhibitors Biological Products / chemistry Drug Design Inhibitory Concentration 50 Staphylococcus aureus / enzymology Transferases / antagonists & inhibitors Transferases (Other Substituted Phosphate Groups) Tunicamycin / chemistry
Antibacterial Enzyme inhibitor Natural products Nucleoside Structure-activity relationship

Journal

Bioorganic & medicinal chemistry
ISSN: 1464-3391
Titre abrégé: Bioorg Med Chem
Pays: England
ID NLM: 9413298

Informations de publication

Date de publication:
15 04 2019
Historique:
received: 07 01 2019
revised: 30 01 2019
accepted: 16 02 2019
pubmed: 10 3 2019
medline: 13 3 2020
entrez: 10 3 2019
Statut: ppublish

Résumé

Elucidating a structure-activity relationship study by evaluating a series of truncated analogues is a simple but important and effective tactic in medicinal chemistry based on natural products with a large and complex chemical structure. In this study, a series of truncated analogues of tunicamycin V were designed and synthesized and their MraY inhibitory activity was investigated in order to gain insight into the effect of these moieties on MraY inhibition.

Identifiants

DOI: 10.1016/j.bmc.2019.02.035 PMID: 30850266
pubmed: 30850266
pii: S0968-0896(18)31813-3
doi: 10.1016/j.bmc.2019.02.035
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
Biological Products 0
Tunicamycin 11089-65-9
Transferases EC 2.-
Transferases (Other Substituted Phosphate Groups) EC 2.7.8.-
mraY protein, Bacteria EC 2.7.8.13

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1714-1719

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Kazuki Yamamoto (K)

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.

Akira Katsuyama (A)

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.

Satoshi Ichikawa (S)

Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan. Electronic address: ichikawa@pharm.hokudai.ac.jp.

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Atomic view of photosynthetic metabolite permeability pathways and confinement in synthetic carboxysome shells.

Daipayan Sarkar, Christopher Maffeo, Markus Sutter et al.
1.00
Photosynthesis Ribulose-Bisphosphate Carboxylase Carbon Dioxide Molecular Dynamics Simulation Cyanobacteria

Management of the infected total elbow arthroplasty.

Joaquin Sanchez-Sotelo
1.00
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines bactériennes › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Techniques d'investigation › Développement de médicament › Découverte de médicament › Conception de médicament › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes toxicologiques › Concentration inhibitrice 50 › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Cocci à Gram positif › Staphylococcaceae › Staphylococcus › Staphylococcus aureus › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Phosphotransferases › Transferases (other substituted phosphate groups) › Structural requirement of tunicamycin V for...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Tunicamycine › Structural requirement of tunicamycin V for...